Study Targeting EGFR Resistance Mechanisms in NSCLC
Conditions: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Neoplasms; Neoplasms by Site; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; EGFR T790M; EGFR C797S; EGFR L858R; EGFR Gene Mutation; EGF-R Positive Non-Small Cell Lung Cancer; EGFR Exon 19 Deletion; EGFR Mutation Resulting in Tyrosine Kinase Inhibitor Resistance; EGFR Activating Mutation; Protein Kinase Inhibitors; Antineoplastic Agents; Thoracic Neoplasms
Intervention: Drug: BLU-945
Sponsor: Blueprint Medicines Corporation
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
April 29, 2021 /
/ in Oncology